ATE363074T1 - Substrate und screeningverfahren für transportproteine - Google Patents
Substrate und screeningverfahren für transportproteineInfo
- Publication number
- ATE363074T1 ATE363074T1 AT00966735T AT00966735T ATE363074T1 AT E363074 T1 ATE363074 T1 AT E363074T1 AT 00966735 T AT00966735 T AT 00966735T AT 00966735 T AT00966735 T AT 00966735T AT E363074 T1 ATE363074 T1 AT E363074T1
- Authority
- AT
- Austria
- Prior art keywords
- transport proteins
- substrates
- screening methods
- methods
- screening
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Computational Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15407199P | 1999-09-14 | 1999-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE363074T1 true ATE363074T1 (de) | 2007-06-15 |
Family
ID=22549879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00966735T ATE363074T1 (de) | 1999-09-14 | 2000-09-14 | Substrate und screeningverfahren für transportproteine |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7413536B1 (de) |
| EP (1) | EP1212619B1 (de) |
| AT (1) | ATE363074T1 (de) |
| AU (1) | AU7703400A (de) |
| DE (1) | DE60034954D1 (de) |
| WO (1) | WO2001020331A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2405151A1 (en) * | 2000-04-07 | 2001-10-18 | University Of Maryland, Baltimore | Bile acid containing prodrugs with enhanced bioavailability |
| PT1305329E (pt) | 2000-08-05 | 2007-12-24 | Glaxo Group Ltd | Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| MY137522A (en) | 2001-04-30 | 2009-02-27 | Glaxo Group Ltd | Novel anti-inflammatory androstane derivatives. |
| WO2002100344A2 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| WO2002100172A1 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Administration of agents via the pept-2 transporter |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
| NZ535354A (en) | 2002-02-15 | 2008-01-31 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| WO2003102579A2 (fr) * | 2002-05-31 | 2003-12-11 | Commissariat A L'energie Atomique | Methode de criblage de banques de molecules radioactives et ses applications |
| FR2840994B1 (fr) * | 2003-01-22 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| FR2840407B1 (fr) * | 2002-05-31 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20040161424A1 (en) * | 2002-10-08 | 2004-08-19 | Xenoport | Human organic solute transporters |
| EP1567169A4 (de) | 2002-11-04 | 2009-10-21 | Xenoport Inc | Gemcitabin-prodrugs, phramazeutische zusammensetzungen und verwendungen davon |
| US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
| WO2005075992A1 (en) * | 2004-01-30 | 2005-08-18 | Xenoport, Inc. | Mct1 transporter expressed in blood brain barrier cells |
| US7910593B2 (en) * | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| WO2006017351A1 (en) | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
| US7550506B2 (en) | 2004-07-12 | 2009-06-23 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| JP2009510198A (ja) * | 2005-09-26 | 2009-03-12 | インヴィトロジェン コーポレーション | 紫色レーザー励起性色素及びその使用方法 |
| CN101371137B (zh) * | 2006-01-31 | 2013-03-27 | 塞诺菲-安万特股份有限公司 | 测定有机阳离子转运蛋白活性的方法 |
| EP1991702A4 (de) * | 2006-02-17 | 2009-04-22 | Univ Leland Stanford Junior | Sequenzielle reportergen-lumineszenz (srl)-verfahren und zusammensetzung zu ihrer ausführung |
| EP2011880B1 (de) | 2006-04-13 | 2012-10-24 | Chugai Seiyaku Kabushiki Kaisha | Taurintransporter-gen |
| US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
| AU2007333225B2 (en) * | 2006-12-08 | 2014-06-12 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| EP2135946B1 (de) | 2007-03-15 | 2015-12-09 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur polypeptidherstellung |
| US8697397B2 (en) | 2007-08-07 | 2014-04-15 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous protein |
| RU2486245C2 (ru) | 2007-10-15 | 2013-06-27 | Чугаи Сейяку Кабусики Кайся | Способ получения клетки, способной продуцировать гетеропротеины с высоким выходом |
| CA2703493C (en) * | 2007-10-24 | 2016-11-08 | Chugai Seiyaku Kabushiki Kaisha | A cell for use in production of heteroproteins and production method using the same |
| EP2276479B1 (de) | 2008-04-15 | 2014-07-02 | SineVir Therapeutics LLC | Prodrugs von neuraminidasehemmern |
| JP2012517811A (ja) * | 2009-02-13 | 2012-08-09 | エックス−ボディ インコーポレイテッド | Dnaディスプレイを利用した核酸送達ビヒクルの同定方法 |
| EP3653763A1 (de) | 2009-02-13 | 2020-05-20 | X-Chem, Inc. | Verfahren zur erstellung und durchsuchung von dna-codierten bibliotheken |
| US8741601B2 (en) | 2009-04-22 | 2014-06-03 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell capable of high-yield production of heteroproteins |
| US8367842B2 (en) * | 2009-07-16 | 2013-02-05 | Beckman Coulter, Inc. | Fluorescent dyes and uses thereof |
| JP5561692B2 (ja) * | 2010-03-09 | 2014-07-30 | 国立大学法人群馬大学 | 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法 |
| EP4137137A1 (de) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen |
| US8399262B2 (en) | 2011-03-23 | 2013-03-19 | Darrel A. Mazzari | Biosensor |
| DK2748357T3 (en) | 2011-09-07 | 2018-07-16 | X Chem Inc | Methods for labeling DNA-encoded libraries |
| SG10201909122QA (en) | 2011-10-28 | 2019-11-28 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US20140323412A1 (en) | 2011-10-28 | 2014-10-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| CA2879018A1 (en) | 2012-07-13 | 2014-01-16 | X-Chem, Inc. | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
| CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| CA2907214A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| KR20180084756A (ko) | 2015-12-07 | 2018-07-25 | 지머젠 인코포레이티드 | 코리네박테리움 글루타미컴으로부터의 프로모터 |
| JP2019519241A (ja) * | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | グルコース透過酵素ライブラリーを生成するための方法およびその使用 |
| KR102345899B1 (ko) | 2016-06-30 | 2021-12-31 | 지머젠 인코포레이티드 | 박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도 |
| GB2552460A (en) * | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
| JP7562546B2 (ja) | 2019-02-12 | 2024-10-07 | ミルム ファーマシューティカルズ インコーポレイテッド | 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法 |
| US20230146782A1 (en) * | 2019-08-06 | 2023-05-11 | Du Jessica Xinyun | Deoxycholic acid compounds, pharmaceutical compositions and uses thereof |
| KR20220115927A (ko) | 2019-10-25 | 2022-08-19 | 세르카코르 래버러토리즈, 인크. | 지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5569678A (en) * | 1989-07-31 | 1996-10-29 | Massachusetts Institute Of Technology | Control of wound scar production |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5866123A (en) | 1990-04-13 | 1999-02-02 | Research Development Foundation | Gene encoding cationic amino acid transporter protein |
| US5236902A (en) * | 1990-11-26 | 1993-08-17 | The Governors Of The University Of Alberta | Method and probes for detecting nucleoside transporter and method for producing the probes |
| US5580775A (en) | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| DE4222315A1 (de) | 1992-07-05 | 1994-01-13 | Inst Genbiologische Forschung | DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5658782A (en) | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
| DE4343527A1 (de) | 1993-12-16 | 1995-06-22 | Schering Ag | Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung |
| US5589358A (en) | 1993-12-29 | 1996-12-31 | Univ Wake Forest | Ileal bile acid transporter compositions and methods |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| DE59505727D1 (de) * | 1994-11-12 | 1999-05-27 | Basf Ag | Verfahren zur herstellung von aminen aus verbindungen mit mindestens 3 cyanogruppen |
| JPH11504218A (ja) * | 1995-04-24 | 1999-04-20 | クロマゾーム コーポレーション | 新規代謝経路の生成およびスクリーニングのための方法 |
| ES2299232T3 (es) | 1995-09-11 | 2008-05-16 | La Jolla Cancer Research Foundation | Moleculas que migran hacia un organo o tejido seleccionado in vivo. |
| DE69629385T2 (de) * | 1995-11-10 | 2004-06-09 | Elan Corp. Plc | Peptide, die den transport über gewebe erhöhen und verfahren zu ihrer identifizierung und verwendung |
| US5780264A (en) | 1996-06-06 | 1998-07-14 | The President And Fellows Of Harvard College | Iron transport protein |
| EP0923603A1 (de) * | 1996-07-16 | 1999-06-23 | Novo Nordisk A/S | Oligopeptid-transporter |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| DE69824174T2 (de) | 1997-02-27 | 2005-07-14 | Cellomics, Inc. | Ein system zur zellbasierten reihenuntersuchung |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| JP4129298B2 (ja) | 1997-05-15 | 2008-08-06 | サイトジェン コーポレーション | 胃腸管(git)輸送受容体に結合するランダムペプチド、及び関連した方法 |
| CA2297413A1 (en) * | 1997-07-15 | 1999-01-28 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
-
2000
- 2000-09-14 EP EP00966735A patent/EP1212619B1/de not_active Expired - Lifetime
- 2000-09-14 US US09/661,927 patent/US7413536B1/en not_active Expired - Fee Related
- 2000-09-14 DE DE60034954T patent/DE60034954D1/de not_active Expired - Lifetime
- 2000-09-14 AU AU77034/00A patent/AU7703400A/en not_active Abandoned
- 2000-09-14 WO PCT/US2000/025439 patent/WO2001020331A1/en not_active Ceased
- 2000-09-14 AT AT00966735T patent/ATE363074T1/de not_active IP Right Cessation
-
2008
- 2008-07-14 US US12/172,801 patent/US20090221442A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1212619A4 (de) | 2004-12-08 |
| US20090221442A1 (en) | 2009-09-03 |
| EP1212619A1 (de) | 2002-06-12 |
| EP1212619B1 (de) | 2007-05-23 |
| WO2001020331A9 (en) | 2002-10-03 |
| DE60034954D1 (de) | 2007-07-05 |
| US7413536B1 (en) | 2008-08-19 |
| AU7703400A (en) | 2001-04-17 |
| WO2001020331A1 (en) | 2001-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE363074T1 (de) | Substrate und screeningverfahren für transportproteine | |
| DE60232688D1 (de) | Grenzflächen-biomaterialien | |
| NO20043245L (no) | Bindingsproteiner som biosensorer | |
| DE60226797D1 (de) | Instrument zum Einbringen von Befestigungselementen für Transplantate | |
| WO2007120699A3 (en) | Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals | |
| EP1687283A4 (de) | Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung | |
| DE69925276D1 (de) | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen | |
| DE60137203D1 (de) | Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung | |
| DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
| DE60005787D1 (de) | Wasserlösliche rhodaminfarbstoffe und ihre konjugate | |
| ATE233762T1 (de) | Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung | |
| ATE352784T1 (de) | Verfahren zum screenen für gpr40-liganden | |
| ITRM980303A0 (it) | Composizione contenente radioisotopi immobilizzati su particelle solide utile in particolare per la biancheria clinica in patologie | |
| TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
| DE59806371D1 (de) | Kontrastmittel für das infarkt- und nekroseimaging | |
| WO1999050459A3 (en) | High throughput in vitro screening assays for transcription modulators | |
| DK1049721T3 (da) | Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse | |
| MXPA03011898A (es) | Ensayo de seleccion in vitro para ?- secretasa. | |
| WO2001008707A3 (de) | Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen | |
| ATE252574T1 (de) | Benzofuran-2-ones als färbemittel für organische materialien | |
| DE69913533D1 (de) | Reagentien für cyp2d fluoreszenztest | |
| MXPA04004018A (es) | Metodos de separacion por exclusion para toxicidad de compuestos de prueba. | |
| NO20025738D0 (no) | Metode | |
| DK1171444T3 (da) | Pyridothienodiazepiner, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse | |
| DE60332076D1 (de) | Doppelmessverfahren zur Anzeige des Inhalts von Poststücken |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |